We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

Precision Medicine to Improve the Risk and Benefit of Cancer Care Genetic Factors in Vincristine-Related Neuropathy

Howard L. McLeod, PharmD1,2
[+] Author Affiliations
1DeBartolo Family Personalized Medicine Institute, Moffitt Cancer Center, Tampa, Florida
2Xiangya Hospital, Institute of Clinical Pharmacology, Central South University, Changsha, China
JAMA. 2015;313(8):803-804. doi:10.1001/jama.2015.1086.
Text Size: A A A
Published online


The past decade has seen important advances in the treatment of many cancers, with curative therapies for a few and extension of quantity and quality of life for others.13 For example, clarifying the role of both growth factor cell signaling and immunologic checkpoints in advanced melanoma has produced kinase inhibitors and immunotherapy drugs that each produce longer patient survival than any previous treatments. These improvements reflect efforts in pharmacology and cancer biology and the success of translating the biochemical, pharmacological, immunological, and molecular findings into treatments. This has allowed the practical emergence of personalized medicine for cancer management, whereby genetic variants, gene expression, and other patient factors allow for more objective selection of therapeutic regimens, individualized dosing of drugs, and the possibility of avoiding drug toxicity.1

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

1 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles